This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH028. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.